Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20768654 | 1.00 | PTPRB (0.47) | PTPRBTSHRMAPTLMNASMN1; SMN2 | |
| SCHEMBL25534610 | 0.85 | SMN1; SMN2 (0.47) | PTPRBTSHRMAPTLMNASMN1; SMN2 | |
| SCHEMBL20768546 | 0.85 | RIPK1 (0.44) | PPARGPPARARIPK1 | |
| SCHEMBL20768547 | 0.85 | RIPK1 (0.44) | PPARGPPARARIPK1 | |
| SCHEMBL16805949 | 0.83 | GAA (0.46) | TSHRSMN1; SMN2HTTCYP1A2CYP2C9 | |
| SCHEMBL28995700 | 0.82 | PPARG (0.45) | TSHRLMNASMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL17619268 | 0.82 | PPARG (0.45) | TSHRLMNASMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL30280602 | 0.80 | GPR88 (0.47) | CYP1A2CYP2C9CYP2C19RIPK1 | |
| SCHEMBL1553363 | 0.79 | CTSS (0.47) | PPARGPPARARIPK1 | |
| SCHEMBL2011973 | 0.79 | CTSS (0.47) | PPARGPPARARIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348386-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348386-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348386-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| EP-4234552-A2 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | Raze Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3426244-B1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11535593-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-11535593-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-20220017464-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2022-01-20 | — | — | US | disclosed |
| US-20220017464-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2022-01-20 | — | — | US | disclosed |
| US-11014882-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-11014882-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20190071400-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2019-03-07 | — | — | US | disclosed |
| US-20190071400-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2019-03-07 | — | — | US | disclosed |
| EP-3426244-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | Raze Therapeutics Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017156179-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017156179-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348386-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | PTPRB 1335/4885TSHR 4686/4885MAPT 2286/4885 |
| US-11535593-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | PHGDH, G6PD, PGD | PTPRB 1335/4885TSHR 4686/4885MAPT 2286/4885 |
| US-11014882-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | PHGDH, G6PD, PGD | PTPRB 1335/4885TSHR 4686/4885MAPT 2286/4885 |
| US-20190071400-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | PTPRB 1335/4885TSHR 4686/4885MAPT 2286/4885 |
| US-20220017464-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | PTPRB 1335/4885TSHR 4686/4885MAPT 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.